EU court confirms €60m fine for Teva

Luxemboug court agrees with European Commission that ‘beneficial arrangement’ between Teva and Cephalon delayed generic market entry of sleep disorder drug | Teva and subsidiary Cephalon to pay around €30m each plus costs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva and Eli Lilly end patent clash over migraine drug

28 November 2023 Rival drugmakers have dropped lawsuit following invalidation of Teva patents in September | Move comes after judge overturned jury verdict handing $176.5m to Teva.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

EU court confirms €60m fine for Teva

More on this story

Editor's picks

Editor's picks

More features